论文部分内容阅读
目的观察骨化三醇联合缬沙坦治疗乙型肝炎病毒相关性肾炎的疗效。方法将乙型肝炎病毒相关性肾炎患者36例随机分为2组,每组18例,治疗组给予骨化三醇联合缬沙坦治疗,对照组给予缬沙坦治疗。检测治疗前后2组患者的血压值、24h尿蛋白、血肌酐、血钙、血磷、C反应蛋白(CRP)以及血浆肾素(PRA)水平。结果治疗12周后,2组血压、24h尿蛋白、PRA及治疗组CRP较治疗前均显著下降(P<0.05),2组血肌酐、血钙、血磷及对照组CRP与治疗前比较差异均无统计学意义(P>0.05)。治疗后治疗组24h尿蛋白、CRP、PRA均显著低于对照组,差异均有统计学意义(P<0.05)。结论骨化三醇联合缬沙坦能有效降低乙型肝炎病毒相关性肾小球肾炎患者的尿蛋白。
Objective To observe the curative effect of calcitriol combined with valsartan on hepatitis B virus associated nephritis. Methods Thirty-six patients with hepatitis B virus-associated nephritis were randomly divided into 2 groups (18 in each group). The treatment group was treated with calcitriol combined with valsartan and the control group with valsartan. Blood pressure, 24h urinary protein, serum creatinine, serum calcium, serum phosphorus, C-reactive protein (CRP) and plasma renin (PRA) levels were measured before and after treatment. Results After 12 weeks of treatment, the blood pressure, 24h urinary protein, PRA and CRP of the two groups were significantly lower than those before treatment (P <0.05). The CRP of serum creatinine, serum calcium, phosphorus and control group were significantly different from those before treatment No statistical significance (P> 0.05). 24h after treatment, urinary protein, CRP and PRA in the treatment group were significantly lower than those in the control group, with statistical significance (P <0.05). Conclusion Calcitriol combined with valsartan can effectively reduce urinary protein in patients with hepatitis B virus associated glomerulonephritis.